Esperion Therapeutics (ESPR) Other Non-Current Liabilities (2012 - 2026)

Esperion Therapeutics' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (changed N/A YoY) and the FY2025 annual result came in at $8.7 million, changed N/A from the prior year.
• Other Non-Current Liabilities was $8.7 million for Q1 2026 at Esperion Therapeutics, roughly flat from $8.7 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $265.0 million in Q3 2022 and bottomed at $7.4 million in Q2 2025.
• A 5-year average of $168.6 million and a median of $230.4 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 20446.36% — and 2023, when it decreased 13.08%.
• Esperion Therapeutics' Other Non-Current Liabilities stood at $218.8 million in 2022, then climbed by 9.64% to $240.0 million in 2023, then declined by 1.48% to $236.4 million in 2024, then slumped by 96.3% to $8.7 million in 2025, then changed by 0.0% to $8.7 million in 2026.
• Business Quant data shows ESPR's Other Non-Current Liabilities at $8.7 million in Q1 2026, $8.7 million in Q4 2025, and $7.4 million in Q3 2025.